Protalix BioTherapeutics (PLX) Misses Q2 EPS by 17c
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.41 +1.26%
Revenue Growth %: -49.8%
Financial Fact:
NET LOSS FOR THE PERIOD: -7.29M
Today's EPS Names:
DIT, AMC, DPZ, More
Revenue Growth %: -49.8%
Financial Fact:
NET LOSS FOR THE PERIOD: -7.29M
Today's EPS Names:
DIT, AMC, DPZ, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q2 EPS of ($0.25), $0.17 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $6.43 million versus the consensus estimate of $8.3 million.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA expects Apple to top analyst expectations on July 30
- Digital Brands Group adds board member, expands college licensing to 22 schools
- DA Davidson Reiterates Buy Rating on Tractor Supply Company (TSCO) Amid Soft Q2 Expectations
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
